August 11, 2017 / 11:12 AM / a month ago

BRIEF-Ionis to independently advance inotersen and IONIS-FB-L Rx

Aug 11 (Reuters) - Ionis Pharmaceuticals Inc

* Ionis to independently advance inotersen and IONIS-FB-L Rx

* Ionis Pharmaceuticals Inc - Has retained all rights to inotersen and IONIS-FB-L(Rx).

* Ionis Pharmaceuticals - As part of reprioritization of pipeline and strategic review of rare diseases business, GSK declined its options on both drugs

* Ionis Pharmaceuticals Inc - Plans to file for marketing authorization for inotersen this year to support a commercial launch of inotersen in 2018.

* Ionis Pharma- Plans to initiate first phase 2 study with IONIS-FB-L(Rx) in patients with dry amd later this year, studies in other indications in 2018 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below